Memento Brings Home $93M Series A and Bispecific for Retinal Diseases: Eyeing the Next Generation of Ophthalmic Therapies

In a notable development for ophthalmic drug innovation, Memento has raised $93 million in a Series A funding round and acquired a lead bispecific antibody aimed at treating serious retinal diseases. The biotech’s lead asset is engineered to both block vascular endothelial growth factor (VEGF) and activate Tie2, two key mechanisms implicated in vision loss from diseases such as neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).

The Deal: Strategic Financing and Asset Acquisition

The Series A financing, which amounts to an impressive $93 million, signals robust investor appetite for differentiated therapeutic approaches in high-burden eye diseases. Such early-stage capital, particularly amid a sector-wide focus on selectivity and pipeline prioritization, will enable Memento to pursue multi-pronged discovery, preclinical, and clinical development efforts for its bispecific asset and any subsequent programs.

Central to the company’s plans is a candidate that simultaneously targets VEGF—widely recognized as a major promoter of abnormal blood vessel growth in the retina—and activates Tie2, a vascular stabilizing receptor. This dual mechanism aims to not only control pathological vessel proliferation but also promote vascular stability and reduce leakage, both of which contribute to vision preservation and enhanced treatment durability compared to current standards.

The Scientific Rationale: VEGF Blockade and Tie2 Activation

Currently, anti-VEGF therapies dominate the market for nAMD and DME, with products such as ranibizumab and aflibercept offering symptom relief and vision preservation for millions of patients globally. Yet not all patients respond optimally, and many require frequent injections, leading to a persistent need for alternatives with longer duration and complementary modes of action.

By introducing a bispecific antibody with the capacity to both neutralize VEGF and stimulate Tie2, Memento’s program aspires to achieve superior efficacy, extended dosing intervals, and potentially fewer adverse events. The hope is that activating Tie2 could counteract vascular instability and inflammation, thus broadening the therapeutic impact beyond VEGF inhibition alone.

Disease Focus: Retinal Disorders with High Unmet Need

Retinal diseases like neovascular age-related macular degeneration and diabetic macular edema are leading causes of vision loss in older adults and individuals with diabetes. Both conditions are characterized by the formation of abnormal, leaky blood vessels in the retina, driven by unregulated VEGF signaling and compromised vascular integrity. The socioeconomic and quality-of-life impacts for patients can be profound, with current therapies often requiring monthly eye injections and intensive management.

Memento’s clinical focus on these diseases reflects both commercial opportunity and patient urgency. The introduction of new modalities, such as bispecific antibodies, could help reduce the burden on patients, healthcare providers, and payers alike.

Investment Trends: Confidence in Next-Generation Biologics

The $93 million Series A round places Memento among a cohort of new biotechs able to secure significant backing in a challenging macro funding climate. Investors appear to be prioritizing platforms and products that offer clear differentiation and the potential to establish new standards of care. The acquisition of a bispecific antibody program fits well within this paradigm, especially as clinicians and regulators seek evidence for improved outcomes and meaningful innovation, not just incremental gains.

This pattern is further reflected in industry-wide surges in interest for biologics capable of targeting multiple disease pathways simultaneously. As clinical data emerges, Memento’s program could help inform future combination strategies, dosing paradigms, and even broader applications for bispecific technology in inflammatory and degenerative eye diseases.

Looking Ahead: Clinical Trials and Market Impact

Memento intends to rapidly advance its lead bispecific candidate into clinical testing for nAMD and DME. The trial program will aim to demonstrate not only efficacy in preserving or restoring vision but also favorable safety, tolerability, and dosing convenience. Key anticipated milestones will include initial readouts of safety and biological activity, followed by larger phase 2 trials to explore comparative benefit versus existing anti-VEGF agents.

If successful, this next-generation biologic could shift the standard of care, decreasing the injection frequency burden for patients, potentially reaching underserved populations, and providing hope for increased treatment durability. Moreover, regulatory and commercial strategies will need to consider payer receptivity, as cost-effectiveness and real-world utility are increasingly pivotal factors in biopharmaceutical market success.

The Broader Implications

The announcement of Memento’s funding and development plans coincides with growing interest in complex biologics for chronic conditions, especially those with large and aging patient populations. While the investment environment has been challenging for some subsectors, ophthalmology continues to attract funding based on clear unmet need and the potential for high-impact product launches.

Ultimately, Memento’s trajectory will serve as a barometer for investor willingness to support unproven modalities in crowded therapeutic spaces—particularly those offering innovation, scalability, and a clear clinical value proposition. As the company initiates studies in the coming months, stakeholders across biotech, clinical ophthalmology, and patient advocacy groups will be watching for signs that the bispecific approach can deliver on its promises.

Source: BioSpace – Memento brings home $93M series A souvenir, picks up bispecific for eye diseases